FindTrial
Sign In

Folic acid supplementation with Levamlodipine Beslate versus Levamlodipine Beslate alone in Hypertension patients with anxiety

Study for effect and synergic association with MTHFR of Levamlodipine Besylate and folacin in the treatment of hypertension complicated with anxiety

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024705
Enrollment
Unknown
Registered
2019-07-22
Start date
2018-10-01
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Experimental group:levamlodipine beslate + FOLIC ACID
Control group:levamlodipine beslate only

Sponsors

The First People's Hospital of Guangyuan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
36 Years to 72 Years

Inclusion criteria

Inclusion criteria: patients with anxiety symptoms were recruited from hypertension

Exclusion criteria

Exclusion criteria: (1) pregnant; (2) a severe anxiety already on treatment with anti-anxiety drug; (3) a very high risk hypertension; (4) history of strokes; (5) other complication like diabetes, tumor, myocardial infarction.

Design outcomes

Primary

MeasureTime frame
BP;SAS;NO;HCY;MTHFR C677T;—

Countries

China

Contacts

Public ContactHanjun He

The First People's Hospital of Guangyuan

hehanj@163.com+86 13608061656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026